Filing Flows › Arcutis Biotherapeutics (ARQT) › Q2 2026 › vs Q2 2025
Arcutis Biotherapeutics (ARQT) Q2 2026 vs Q2 2025 (year over year)
Arcutis Biotherapeutics's revenue rose $48.4M (+59%) from $81.5M in Q2 2025 to $130M in Q2 2026. The biggest changes: ZORYVE foam +$28.2M (+72%); ZORYVE cream 0.15% +$9.6M (+66%); ZORYVE cream 0.3% +$7.7M (+28%). Operating margin 12.7% against -17.9% (+30.6 pts).
Arcutis Biotherapeutics, Q2 2026: revenue $130M (+59% year over year), operating margin 12.7%, net earnings $15.0M, operating cash flow $12.6M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 12.7% | -17.9% | +30.6 pts |
| Net margin | 11.6% | -19.5% | +31.0 pts |
| Free cash flow margin | 9.6% | 0.3% | +9.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| ZORYVE foam | $67.4M | $39.2M | $28.2M | +72% |
| ZORYVE cream 0.3% | $35.3M | $27.7M | $7.7M | +28% |
| ZORYVE cream 0.15% | $24.2M | $14.6M | $9.6M | +66% |
| ZORYVE cream 0.05% | $2.9M | $0 | $2.9M | — |
| Revenue | $130M | $81.5M | $48.4M | +59% |
| Operating profit | $16.4M | −$14.6M | $31.0M | — |
| Costs & expenses | $113M | $96.1M | $17.3M | +18% |
| Pre-tax earnings | $15.1M | −$15.5M | $30.7M | — |
| Other expense, net | $1.3M | $933K | $351K | +38% |
| Cost of revenue | $10.9M | $7.5M | $3.4M | +46% |
| Research & development | $20.4M | $19.5M | $902K | +5% |
| SG&A | $82.1M | $69.2M | $13.0M | +19% |
| Net earnings | $15.0M | −$15.9M | $30.9M | — |
| Income tax | $136K | $342K | −$206K | -60% |
| Operating cash sources | $27.8M | −$5.4M | $33.2M | — |
| Share-based compensation | $12.8M | $10.5M | $2.3M | +22% |
| Working capital & other | $15.1M | −$5.7M | $20.9M | — |
| Operating cash flow | $12.6M | $324K | $12.3M | 39× |
| Free cash flow (OCF − capex) | $12.5M | $246K | $12.2M | 51× |
| Capital expenditures | $158K | $78K | $80K | +103% |
Questions
How much did Arcutis Biotherapeutics's revenue grow year over year in Q2 2026?
Arcutis Biotherapeutics's revenue rose $48.4M (+59%) from $81.5M in Q2 2025 to $130M in Q2 2026.
What drove Arcutis Biotherapeutics's revenue change in Q2 2026?
ZORYVE foam +$28.2M (+72%); ZORYVE cream 0.15% +$9.6M (+66%); ZORYVE cream 0.3% +$7.7M (+28%).